APA (7th ed.) Citation

EY, C., KY, L., DY, Y., & AL, M. (2025). Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion. Pediatric nephrology (Berlin, Germany), 40(3), 711. https://doi.org/10.1007/s00467-024-06570-8

Chicago Style (17th ed.) Citation

EY, Chan, Lin KY, Yap DY, and Ma AL. "Obinutuzumab as a Viable Therapeutic Strategy in Rituximab-refractory Childhood Frequently Relapsing, Steroid-dependent Nephrotic Syndrome That Relapsed During B-cell Depletion." Pediatric Nephrology (Berlin, Germany) 40, no. 3 (2025): 711. https://doi.org/10.1007/s00467-024-06570-8.

MLA (9th ed.) Citation

EY, Chan, et al. "Obinutuzumab as a Viable Therapeutic Strategy in Rituximab-refractory Childhood Frequently Relapsing, Steroid-dependent Nephrotic Syndrome That Relapsed During B-cell Depletion." Pediatric Nephrology (Berlin, Germany), vol. 40, no. 3, 2025, p. 711, https://doi.org/10.1007/s00467-024-06570-8.